MX2021008022A - Proteínas heterodiméricas para modular células t gamma delta. - Google Patents

Proteínas heterodiméricas para modular células t gamma delta.

Info

Publication number
MX2021008022A
MX2021008022A MX2021008022A MX2021008022A MX2021008022A MX 2021008022 A MX2021008022 A MX 2021008022A MX 2021008022 A MX2021008022 A MX 2021008022A MX 2021008022 A MX2021008022 A MX 2021008022A MX 2021008022 A MX2021008022 A MX 2021008022A
Authority
MX
Mexico
Prior art keywords
cells
heterodimeric proteins
gamma delta
modulating gamma
modulating
Prior art date
Application number
MX2021008022A
Other languages
English (en)
Spanish (es)
Inventor
George Fromm
Taylor Schreiber
Silva Suresh De
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of MX2021008022A publication Critical patent/MX2021008022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021008022A 2019-01-07 2020-01-07 Proteínas heterodiméricas para modular células t gamma delta. MX2021008022A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962789344P 2019-01-07 2019-01-07
US201962876346P 2019-07-19 2019-07-19
US201962941176P 2019-11-27 2019-11-27
PCT/US2020/012589 WO2020146393A1 (en) 2019-01-07 2020-01-07 Heterodimeric proteins for modulating gamma delta t cells

Publications (1)

Publication Number Publication Date
MX2021008022A true MX2021008022A (es) 2021-08-05

Family

ID=71521410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008022A MX2021008022A (es) 2019-01-07 2020-01-07 Proteínas heterodiméricas para modular células t gamma delta.

Country Status (13)

Country Link
US (2) US20220025000A1 (enExample)
EP (1) EP3902557A4 (enExample)
JP (1) JP2022516964A (enExample)
KR (1) KR20210113244A (enExample)
CN (1) CN113329759A (enExample)
AU (1) AU2020205965A1 (enExample)
BR (1) BR112021013193A2 (enExample)
CA (1) CA3125474A1 (enExample)
IL (1) IL284658A (enExample)
MX (1) MX2021008022A (enExample)
PH (1) PH12021551475A1 (enExample)
SG (1) SG11202106895UA (enExample)
WO (1) WO2020146393A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116801897A (zh) * 2020-10-26 2023-09-22 沙塔克实验室有限公司 包含嗜乳脂蛋白的同二聚体和异二聚体蛋白
CA3199224A1 (en) * 2020-11-19 2022-05-27 George FROMM Methods of identifying gamma delta t cell-modulating agents
CA3212277A1 (en) * 2021-03-16 2022-09-22 Taylor Schreiber Gamma delta t-cell costimulation
WO2023154812A1 (en) * 2022-02-09 2023-08-17 Shattuck Labs, Inc. Multispecific heterodimeric proteins
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024191989A1 (en) * 2023-03-14 2024-09-19 Shattuck Labs, Inc. Treatment of b cell-mediated diseases by activating cd20-targeted gamma delta t cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223601A1 (en) 2002-04-12 2003-10-27 King's College London ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4
JP2006502978A (ja) 2002-06-17 2006-01-26 ワイス ブチロフィリン４またはｂ７−ｌ１によるｔ細胞活性化阻害
EP1702622A1 (en) 2005-03-18 2006-09-20 CONARIS research institute AG Soluble BTNL2 protein useful to inhibit inflammatory disorders
WO2007110205A2 (en) * 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2008154516A2 (en) 2007-06-11 2008-12-18 The Board Of Regents, The Universtity Ot Texas System Btnl2 fusion protein for t-cell activity modulation
GB0717101D0 (en) 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
EP3663318A1 (en) * 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2011237365B2 (en) 2010-04-09 2015-01-29 Amgen Inc. BTNL9 proteins, nucleic acids, and antibodies and uses thereof
CA2796633C (en) * 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
EP2797952B1 (en) 2011-12-28 2019-02-27 ImmunoQure AG Method of providing monoclonal auto-antibodies with desired specificity
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
AU2013371826A1 (en) 2013-01-01 2015-08-13 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
GB201300052D0 (en) 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-suppressive dendritic cells
GB201300049D0 (en) 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
CA2916895C (en) 2013-07-03 2022-08-09 Immunoqure Ag Human anti-il-32 antibodies
AU2014354587A1 (en) 2013-11-29 2016-06-02 Csl Limited Method of treating cancer
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
EP3223849A4 (en) 2014-11-25 2018-05-30 Albert Einstein College of Medicine, Inc. Btnl9 and ermap as novel inhibitors of the immune system for immunotherapies
EP3173092B1 (en) 2015-04-22 2019-06-26 CureVac AG Rna containing composition for treatment of tumor diseases
WO2016191305A1 (en) * 2015-05-22 2016-12-01 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
BR112018006578A2 (pt) 2015-10-01 2018-12-26 Heat Biologics, Inc. composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
CA3003077A1 (en) 2015-10-30 2017-05-04 King's College London Expansion of non-haematopoietic tissue-resident .gamma.delta. t cells and uses of these cells
MX2018006613A (es) 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
GB201521389D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
CN116769054A (zh) * 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
KR20180130541A (ko) 2016-03-29 2018-12-07 주식회사 에스티큐브앤컴퍼니 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
US11634493B2 (en) * 2016-11-02 2023-04-25 Beijing Proteome Research Center Tumor immunotherapy target and application thereof
WO2018201130A1 (en) 2017-04-28 2018-11-01 The Brigham And Women's Hospital, Inc. Targeting gamma-delta t cells in obesity and cachexia
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
KR20250036941A (ko) 2017-05-31 2025-03-14 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
EP3635007A1 (en) 2017-06-06 2020-04-15 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
US20200297871A1 (en) 2017-09-15 2020-09-24 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
AU2018335955B2 (en) 2017-09-21 2024-12-12 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for BTN2 and uses thereof
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells

Also Published As

Publication number Publication date
AU2020205965A1 (en) 2021-07-01
US20220025000A1 (en) 2022-01-27
SG11202106895UA (en) 2021-07-29
EP3902557A4 (en) 2023-06-07
US20230020258A1 (en) 2023-01-19
KR20210113244A (ko) 2021-09-15
CA3125474A1 (en) 2020-07-16
BR112021013193A2 (pt) 2021-09-28
IL284658A (en) 2021-08-31
PH12021551475A1 (en) 2022-05-02
EP3902557A1 (en) 2021-11-03
JP2022516964A (ja) 2022-03-03
CN113329759A (zh) 2021-08-31
WO2020146393A1 (en) 2020-07-16
US11643447B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
MX2019011570A (es) Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2020004568A (es) Combinación de una terapia celular y un inhibidor de gamma secretasa.
MX2021002294A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.
CR20140586A (es) Celulas para producir iduronato-2-sulfatasa recombinante
EP4545143A3 (en) Early intervention methods to prevent or ameliorate toxicity
EP4286511A3 (en) Method to treat cancer with engineered t-cells
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
PH12021551475A1 (en) Heterodimeric proteins for modulating gamma delta t cells
MX2018003353A (es) Terapias con celulas cart con una eficacia mejorada.
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
EP4527922A3 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
EA201791782A1 (ru) 4,6-диаминопиридо[3,2-d]пиримидиновые соединения, модулирующие toll-подобные рецепторы
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
SV2017005416A (es) Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
CL2021000446A1 (es) Métodos para la normalización del metabolismo de aminoácidos